mRNA melanoma vaccine cuts metastasis risk by 60%, approval approaching

An mRNA melanoma vaccine used alongside immunotherapy reduces the risk of distant metastasis by 60% compared to standard treatment, according to oncologist Prof. Piotr Rutkowski. Trial results show recurrence rates approaching zero. The vaccine could receive regulatory approval soon.